Unlike previous immunotherapy approaches, anti-PD-1/PD-L1 treatments can regulate the immune feedback at the lump place, address immune deficiencies caused by tumor progression, and restore active tumor immunity (5). The gene discussed is CD274; the disease is neoplasm.